Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. Conti.
Clinical Genitourinary Cancer | 2018
Stefano Luzzago; Giuseppe Petralia; Gennaro Musi; M. Catellani; Sarah Alessi; Ettore Di Trapani; Francesco Mistretta; Alessandro Serino; A. Conti; Paola Pricolo; Sebastiano Nazzani; Vincenzo Mirone; D.V. Matei; E. Montanari; Ottavio De Cobelli
Purpose: To understand the multiparametric magnetic resonance imaging (mpMRI) interreader agreement between radiologists of peripheral and academic centers and the possibility to avoid prostate biopsies according to magnetic resonance imaging second opinion. Patients and Methods: This prospective observational study enrolled 266 patients submitted to mpMRI at nonacademic centers for cancer detection or at active surveillance begin. Images obtained were reviewed by 2 unblinded radiologists with 8 and 5 years’ experience on mpMRI, respectively. We recorded Prostate Imaging Reporting and Data System (PI‐RADS) v2 categories and management strategy changes after mpMRI rereadings. Interreader agreement was assessed by the Cohen kappa. For mpMRI second opinion, positive predictive value and negative predictive value were calculated. Results: In the original readings, no lesions (ie, PI‐RADS < 2) were observed in 17 cases (6.5%). Reported index lesion (IL) PI‐RADS category was 2 in 23 (8.5%), 3 in 85 (32%), 4 in 98 (37%), and 5 in 13 (5%) men, respectively. It is noteworthy that in 30 examinations (11%), an IL was recognized by radiologists, but a suspicious score was not assigned. According to first reading of mpMRI, initial clinical strategy included performing a targeted (226; 85%) or a systematic biopsy (8; 3%), scheduling the patient to an active surveillance program without repeat biopsy (10; 4%), or monitoring prostate‐specific antigen without prostate sampling (22; 8%). The mpMRI rereads did not change IL PI‐RADS category in 91 cases (38.5%), although in 20 (8.5%) and 125 (53%) IL PI‐RADS was upgraded or downgraded, respectively (&kgr; = 0.23). The clinical management changed in 113 patients (48%) (&kgr; = 0.2). Overall, 102 targeted biopsies (51%) were avoided and 72 men (34.5%) were not submitted to biopsy after mpMRI second opinion. Positive predictive value and negative predictive value of the mpMRI rereading were 58% and 91%, respectively. Major limitations of the study are limited‐time follow‐up and the lack of a standard of reference for some men, who were not submitted to biopsy according to mpMRI second opinion. Conclusion: There is an important level of discordance between mpMRI reports. According to imaging second opinion, roughly half of targeted biopsies could be avoidable and 34.5% of men could skipped prostate sampling. Prospective randomized trials are needed to confirm our findings. MICRO‐ABSTRACT In this prospective observational study, we observed a significant level of discordance between multiparametric magnetic resonance imaging of the prostate reports in peripheral and subspecialized centers. If confirmed by further prospective randomized trials, multiparametric magnetic resonance imaging second opinion by expert radiologists could become a useful tool to deliver the best management for patients, avoiding 52% of targeted and 33.5% of total biopsies.
European Urology Supplements | 2017
Gennaro Musi; A. Conti; Andrea Russo; F.A. Mistretta; A. Serino; V. Tringali; M. Catellani; G. Cozzi; R. Bianchi; M. Delor; Matteo Ferro; Victor Matei; O. De Cobelli
Introduction and Objectives Traditional surgical treatment of penile carcinoma was amputation of the glans, resulting in organ dysfunction and disfigurement, with a strong impact on patient’s quality of life. Several conservative treatment modalities have been introduced with the goal of achieving conservative treatment. We present the initial experience with thulium laser excision of early stage penile lesions.
World Journal of Urology | 2018
Gennaro Musi; Andrea Russo; A. Conti; Francesco Mistretta; Ettore Di Trapani; Stefano Luzzago; R. Bianchi; Giuseppe Renne; Stefano Ramoni; Matteo Ferro; Deliu Victor Matei; Marco Cusini; Luca Carmignani; Ottavio De Cobelli
European Urology Supplements | 2018
M. Catellani; S. Luzzago; F.A. Mistretta; A. Conti; E. Di Trapani; G. Cozzi; R. Bianchi; Sarah Alessi; Antonio Cioffi; Paola Pricolo; Matteo Ferro; D.V. Matei; G. Petralia; Gennaro Musi; O. De Cobelli
European Urology Supplements | 2018
S. Luzzago; M. Catellani; F.A. Mistretta; A. Conti; E. Di Trapani; G. Cozzi; R. Bianchi; Giovanni Cordima; Sarah Alessi; Matteo Ferro; M. Delor; D.V. Matei; G. Petralia; Gennaro Musi; O. De Cobelli
European Urology Supplements | 2018
J. Ghahhari; Luca Cindolo; P. Spiess; J. Chipollini; P. Nyirády; Paolo Chiodini; J. Varga; Pasquale Ditonno; Michele Battaglia; C. De Nunzio; G. Tema; A. Veccia; Alessandro Antonelli; Gennaro Musi; O. De Cobelli; A. Conti; Salvatore Micali; M. Maestro; M. Alves Lima; A. Tracey; R. Autorino; Petros Sountoulides; Maida Bada; Michele Marchioni; Luigi Schips
European Urology Supplements | 2018
M. Delor; Gennaro Musi; G. Cozzi; R. Bianchi; E. Di Trapani; M. Turetti; A. Conti; M. Catellani; Danilo Bottero; O. De Cobelli
European Urology Supplements | 2018
M. Catellani; S. Luzzago; F.A. Mistretta; A. Conti; E. Di Trapani; R. Bianchi; G. Cozzi; Matteo Ferro; Gennaro Musi; D.V. Matei; O. De Cobelli
European Urology Supplements | 2018
S. Luzzago; M. Catellani; F.A. Mistretta; A. Conti; Paola Pricolo; A. Serino; R. Bianco; Sarah Alessi; A. Brescia; E. Di Trapani; Matteo Ferro; D.V. Matei; G. Petralia; Gennaro Musi; O. De Cobelli
European Urology Supplements | 2018
F.A. Mistretta; A. Conti; M. Catellani; M. Delor; A. Serino; S. Luzzago; G. Cozzi; Matteo Ferro; D.V. Matei; Gennaro Musi; E. Verri; Barbara Alicja Jereczek-Fossa; O. De Cobelli